Brief:

Brief: It is well known that neurological diseases that affect the brain or other components of the central nervous system are among the most devastating and complex conditions plaguing mankind today. For thousands of years, damage to the adult central nervous system (CNS) in humans has been regarded as an ��ailment which cannot be treated��. In the adult mammalian CNS, most injured axons do not regenerate, reflecting a major hurdle for functional recovery after trauma. Numerous efforts over more than a century have been devoted to uncover the underlying mechanisms of regeneration failure. The discovery of neural and glial precursor cells in the adult brain and their ability to grow after injury trumped this assumption. However, in most cases, only small numbers of injured CNS axons can regenerate, consistent with the idea that lack of regeneration in the adult CNS is an intrinsic property of the injured neurons. Therefore, a major challenge has been to define the underlying cellular and molecular mechanisms that determine neuronal intrinsic regenerative ability, with the goal to construct a foundation for designing therapeutic neural repair strategies. Many signaling pathways (including Ras homolog gene/Rho-associated coiled coil-forming protein kinase (Rho-ROCK), Notch, MAPK, Wnt/��-catenin, mTOR, and ephephrin) participate in and affect repair or regeneration of neurons and axons in the central nervous system. The cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) and Rho-ROCK signaling pathways are key signal transduction pathways for regulating neural and axonal regeneration. SAB collects 149 compounds related to neuroregeneration as Neuroregeneration Compound Library, which can be used for screening of drugs that promote axonal growth and regeneration

Brief: Chemokines are a family of small proteins inducing directed cell migration via specific chemokine receptors, which play important roles in a variety of biological and pathological processes, such as immune surveillance, development, wound healing, bacterial infection, inflammatory reaction, tumor progression and metastasis, etc. Therapeutic strategies based on modulation of chemokine receptor pathways were reported to be promising clinical strategies in the treatment of inflammatory diseases, such as multiple sclerosis and atherosclerosis, psoriasis, inflammatory skin diseases and atopic dermatitis, as well as viral infections, including HIV. Approximately 20 chemokine receptors and 50 chemokines have been identified in humans. Chemokines and their receptors are divided into four families based on the pattern of cysteine residues: CXC, CC, CX3C and XC, where C represents the cysteine and X represents non-cysteine amino acids. Chemokine receptors are seven transmembrane spanning proteins coupled to G-protein-coupled-receptors (GPCRs). These receptors are named based on the chemokine ligands to which they bind. For example, CXC receptors (CXCR1, 2, 3, 4 and 5) bind CXC chemokines, CC receptors (CCR1, 2, 3, 4, 5, 6, 7, 8, 9) bind CC chemokines; CX3C receptor binds CX3C chemokine and lastly, the XC receptor binds the C chemokine. Advances in basic chemokine research have indicated that chemokines and their receptors are the highly promising drug targets for inflammatory and immunological diseases. Antagonizing the chemokine receptor interaction is considered to be beneficial in inflammatory disorders. Currently various chemokine receptor blockers range from monoclonal antibodies, modified chemokines, and low molecular weight receptor antagonists. SAB collects 27 compounds targeting chemokines or chemokine receptors as Chemokine Inhibitors Library, which can be used for research in immune-mediated diseases, and drug screening.

Brief: Coagulation is the process by which blood changes from a liquid to a gel, forming a blood clot. Substances that take part in the coagulation cascade are called clotting factors. The blood clotting process is complex and mainly involves three steps: producing prothrombin activator, prothrombin being converted to thrombin, and fibrinogen being converted to fibrin. Anticlotting mechanisms are important in restricting clot formation to the site of injury. The two major systems are the anticoagulant and fibrinolytic systems. The balance of coagulation and anticlotting mechanism keeps the hemostatic system functioning efficiently. It is currently believed that the anticoagulant mechanism mainly has the barrier function of vascular endothelium, fibrin adsorption, phagocytosis of mononuclear macrophage system and physiological anticoagulant substances. The SABs Cocoagulation and Anticoagulation Compound Library, a unique collection of 153 procoagulation and anticoagulation related compounds, can be used for research in coagulation and anticoagulation mechanisms, and related drug development

Brief: Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. According to the trigger that opens the channel for such ions, they can be classified into Voltage-gated sodium channels and ligand-gated sodium channels. Sodium channels are highly selective for the transport of sodium ions across cell membranes. In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials.Many of the most common neurological disorders, such as epilepsy, migraine, neurodegenerative diseases, and neuropathic pain, involve abnormalities of neuronal excitability. There is a growing body of data that implicates abnormal expression and function of voltage-gated sodium channels (VGSCs) in these disorders. Pharmacological inhibitors of VGSCs have been used for decades to treat epileptic seizures, the most common disease of neuronal excitability, and arrhythmia, and it is becoming increasingly evident that these antiepileptic VGSC blockers might also be efficacious against a broad range of neurological disorders. Sodium channels serve as specific target for a large variety of chemically distinct neurotoxins produced by many different animals and plants. The development of drugs with enhanced selectivity for specific VGSC isoforms might be an effective and novel approach for the treatment of several neurological diseases. SABs Sodium Channel Blockers Library collects 62 reported sodium channel blockers and agonists, and is an ideal tool for screening more selective and efficient drugs targeting potassium channels

Brief: Potassium channels are the most widely distributed type of ion channel and are found in virtually all living organisms. They form potassium-selective pores that span cell membranes. Furthermore, potassium channels are found in most cell types and control a wide variety of cell functions, such as regulation of cellular excitability, neurotransmitter release, protecting cardiac myocytes, and anti-arrhythmia function, and are involved in learning and memory process, and temperature control. Potassium channel blockers is a class of drugs that act by inhibition of potassium efflux through cell membranes, including inorganic ions (Cs, Ba) and organic molecules (TEA, 4-AP), toxins (scorpion venoms, snake venoms, and bee venoms), and potassium channel blockers in clinical use.

Brief: A calcium channel is an ion channel(plasma membrane protein) which shows selective permeability to calcium ions. Calcium channels constitute a large family of voltage- and ligand-operated ion channels. Calcium channels are ubiquitous, they can be found in almost any type of excitable (e.g., muscle, glial cells, neurons, etc.) and most unexcitable cells in a wide variety of species. Functions mediated by calcium channels include contraction of muscle, release of neurotransmitters and hormones by neurons and neuroendocrine cells, and control of gene transcription. They are targets for modulation by many intracellular signaling pathways including G proteins and phosphorylation. Calcium channels play pivotal roles in many human diseases, particularly of the cardiac and nervous systems, including pain, seizure, hypertension and migraine. Pharmacological blockers for some types of calcium channels are known, including clinically used drugs for hypertension and pain. In some cases such calcium channel blockers are highly selective for specific types of calcium channels, but there is great potential for developing more selective and more potent drugs targeting calcium channels. SABs Calcium Channel Library collects the reported calcium channel blockers and agonists, and is an ideal tool for screening more selective and potent drugs targeting calcium channels

Brief: Obesity has become the public health issue of the day��and for good reason. The data outline a dismal picture and a more foreboding future. The prevalence of obesity has doubled in adults and children and tripled in adolescents over the past 2 decades. Two thirds of Americans are overweight or obese. Each year in the United States, 400 000 deaths and $117 billion in health-care and related costs are attributable to obesity. Obesity is a complex, multi-factorial disease that develops from the interaction of genetic, social, behavioral, cultural, physiological, and metabolic factors. It is intimately linked to heart disease, sleep apnea, and certain cancers. Current main options for treatment of obesity including diet, physical exercise, behavioral therapy, and bariatric surgery have some degree of risk. Therefore, there is a strong need to develop a new effective and safe anti-obesity drug.Many pharmaceutical companies have invested substantial capital and labor to develop anti-obesity drugs; however, most of the anti-obesity drugs that have thus far been approved and marketed have ultimately been withdrawn because of their serious adverse effects. Scientists are trying to find and identify safe and effective anti-obesity bioactive ingredients from food or drugs, especially by inhibiting intestinal fat absorption, increasing fat cell metabolism, and enhancing the energy expenditure, such as lipase inhibitors, alpha-glucosidase inhibitors (��GI), and Maltase�\glucoamylase (MGA) inhibitors. Traditional pharmacological monotherapies for obesity, although initially successful in achieving weight loss, are often subject to counter-regulation. This is not surprising given the multiplicity and redundancy of mechanisms involved in appetite regulation and energy homeostasis. It is therefore pertinent to note that combination agents that are designed to simultaneously target more than one biological mechanism might ultimately be more effective in producing sustained weight loss and improvements in comorbidities. Based on the published literature, SAB carefully collects 85 compounds with anti-obesity activity as Anti-obesity Compound Library, which can be used for anti-obesity research and drug discovery

Brief: Although the Chinese herbal compound has achieved certain curative effect in clinical practice, the mechanism of action is hard to be elucidated through experiment due to their complicated components. This has seriously hindered further development and better clinical applications of Chinese medicine. Actually the pharmacological effect of Chinese medicine is realized through its active ingredients. For example, Artemisinin, the active ingredient extracted from a Chinese materia medica Artemisia annua, is the most effective antimalarial drug. Ginsenosides are a class of natural product steroid glycosides and triterpene saponins. Compounds in this family are found almost exclusively in the plant genus Panax (ginseng), which has a long history of use in traditional medicine. Therefore, it is a good and economical way to discover new chemical drugs based on active ingredients and leading compounds separating from Chinese herbal medicine and it may be an available path with less risk. With the continuous development of the traditional Chinese medicine industry in recent years, it is proved that traditional Chinese medicine (TCM) monomers have a marked effect for treating some diseases. Natural Compound Library in Chinese Pharmacopoeia by SAB consists of 564 natural products carefully selected from Chinese Pharmacopoeia (CP) Dictionary, including 246 active ingredients from traditional Chinese herb medicine, such as Danshen (Salvia miltiorrhiza), Eucommia ulmoides, Huangqi (Astragalus), etc. which is a powerful tool for research in antitumor, antibacterial, apoptosis, and autophagy. These Chinese medicine monomers consist of greatly diversified structures, such as Genistein, polyphenols, ��-Carotene, Ursolic acid, Flavonoids, and Saponins, etc. with known bioactivity information that will assist you in improving the drug screening success rate

Brief: Cancer is a well-recognized global health problem responsible for 7.6 million deaths (13% of all deaths) worldwide, which is expected to rise to 13.1 million by 2030. It has long been recognized that natural products represent the richest source of high chemical diversity, providing the basis for identification of novel scaffold structures that serves as starting points for rational anticancer drug design. According to a recent review, 49% of drugs were either natural products or their derivatives that are used in cancer treatment. Moreover, between the year 2005 and 2010, 19 natural product-based drugs have been approved, among which 7, 10 and 2 have been classified as natural product (NP), semi-synthetic NPs and NP-derived drugs, respectively. Natural products have served as an effective source of drugs and drug leads. SAB carefully collects 497 natural products from plants, animals, or microbes with known or potential antitumor activity, which is a powerful tool for your antitumor drug development and lead compounds screening